Alterity Therapeutics Submits September 2026 Corporate Presentation

Alterity Therapeutics Limited, a development-stage biotechnology company, filed a Form 6-K with the SEC on September 23, 2026. The primary purpose of the filing was to submit a Corporate Presentation for September 2026 as Exhibit 99.1. The presentation is intended to provide updates on the company\'s operations and progress to investors and stakeholders. The filing also notes that the report is incorporated by reference into several of the company\'s existing Registration Statements on Form S-8 and Form F-3. No specific clinical trial data, regulatory approvals, or financial results were detailed in the primary text of the 6-K filing itself, which serves as a transmittal document for the corporate presentation. Alterity continues to focus on its development-stage assets, with the presentation likely covering its pipeline and strategic goals for the remainder of 2026.